Neumora Therapeutics, Inc. Common StockNMRANASDAQ
Loading
Year-over-year operating cash flow growth rate
3Y CAGR
+53.1%/yr
Quarterly compound
Percentile
P79
Within normal range
vs 3Y Ago
3.6x
Strong expansion
Streak
1 qtr
Consecutive declineStable
| Period | Value |
|---|---|
| Q3 2025 | 11.01% |
| Q2 2025 | 11.85% |
| Q1 2025 | -18.09% |
| Q4 2024 | -50.34% |
| Q3 2024 | 40.38% |
| Q2 2024 | -30.74% |
| Q1 2024 | 16.50% |
| Q4 2023 | -7.68% |
| Q3 2023 | -54.00% |
| Q2 2023 | 6.11% |
| Q1 2023 | -8.81% |
| Q4 2022 | -17.86% |
| Q3 2022 | 3.07% |
| Q2 2022 | 17.42% |
| Q1 2022 | -9.66% |
| Q4 2021 | -70.09% |
| Q3 2021 | -27.20% |
| Q2 2021 | 11.00% |
| Q1 2021 | 7.68% |
| Q4 2020 | 0.00% |